Get the Stockscreener App
24.69
4.22%
1.00
Avalyn Pharma Inc stock is traded at $24.69, with a volume of 53,759.
It is up +4.22% in the last 24 hours and down -27.98% over the past month.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
See More
Previous Close:
$23.69
Open:
$23.88
24h Volume:
53,759
Relative Volume:
0.14
Market Cap:
$1.09B
Revenue:
Net Income/Loss:
P/E Ratio:
-
EPS:
-
Net Cash Flow:
1W Performance:
-4.00%
1M Performance:
-27.98%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$23.59
$25.14
1-Week Range:
$22.68
$26.32
52-Week Range:
$22.68
$40.17
Avalyn Pharma Inc Stock (AVLN) Company Profile
Name
Avalyn Pharma Inc
Sector
Industry
Phone
(206) 707-0340
Address
105 W FIRST ST., BOSTON
Compare AVLN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVLN
Avalyn Pharma Inc
|
24.69 | 1.09B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
509.86 | 129.23B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.75 | 94.92B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.00 | 82.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.32 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.60 | 42.04B | 5.76B | 514.49M | 1.10B | 4.4813 |
Avalyn Pharma Inc Stock (AVLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-02-26 | Initiated | Raymond James | Outperform |
| May-26-26 | Initiated | Evercore ISI | Outperform |
| May-26-26 | Initiated | Guggenheim | Buy |
| May-26-26 | Initiated | Jefferies | Buy |
| May-26-26 | Initiated | Morgan Stanley | Overweight |
Avalyn Pharma Inc Stock (AVLN) Latest News
LB Pharmaceuticals Inc (LBRX) Stock Price & News - Syfe
Neurogene Inc. (NGNE) Stock Price & News - Syfe
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile - Stock Titan
Avalyn Pharma (AVLN) adds ex-FDA leader to its board - Stock Titan
Avalyn Pharma (NASDAQ:AVLN) Rating Increased to Hold at Wall Street Zen - MarketBeat
Bank of New York Mellon Corp Acquires New Shares in Avalyn Pharma Inc. $AVLN - MarketBeat
Nuvectis Pharma, Inc. (NVCT) Stock Price & News - Syfe
AQST Stock Price, Quote & News - Syfe
Avalyn Pharma presents AP01 lung distribution modeling data By Investing.com - Investing.com Canada
Avalyn Pharma presents AP01 lung distribution modeling data By Investing.com - Investing.com Australia
Avalyn Pharma presents AP01 lung distribution modeling data By Investing.com - Investing.com India
Avalyn Pharma presents AP01 lung distribution modeling data - investing.com
Avalyn Pharma presents AP01 lung distribution modeling data By Investing.com - Investing.com UK
People with lung scarring are willing to travel for trials, Avalyn survey finds - Stock Titan
Morgan Stanley's New York healthcare event will include Avalyn Sept. 14 - Stock Titan
Avalyn Pharma Inc. (NASDAQ:AVLN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
AVLN Options Overview History for Avalyn Pharma Stock - Barchart.com
Braidwell LP Invests $26.38 Million in Avalyn Pharma Inc. $AVLN - MarketBeat
Montanova Capital LLC Takes Position in Avalyn Pharma Inc. $AVLN - MarketBeat
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026 - Barchart.com
Avalyn will present a model of how an inhaled treatment may spread through the lungs - Stock Titan
AVLN Options Volatility — NASDAQ:AVLN - TradingView
AVLN Options Chain — NASDAQ:AVLN - TradingView
Avalyn Pharma (NASDAQ:AVLN) Sets New 1-Year HighHere's Why - MarketBeat
Avalyn Pharma (NASDAQ:AVLN) Cut to Sell at Wall Street Zen - MarketBeat
Novo Holdings A/S (AVLN) discloses 8.8% beneficial stake in Avalyn Pharma - Stock Titan
Jefferies Maintains Avalyn Pharma(AVLN.US) With Buy Rating, Maintains Target Price $52 - Moomoo
Morgan Stanley Maintains Avalyn Pharma(AVLN.US) With Buy Rating, Raises Target Price to $57 - Moomoo
Avalyn Pharma (NASDAQ:AVLN) Hits New 52-Week High Following Better-Than-Expected Earnings - MarketBeat
AVLN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Avalyn Pharma Inc. Common Stock (NASDAQ: AVLN) Stock Price, News & Analysis - Kalkine
Avalyn Pharma Inc. Common Stock (NASDAQ: AVLN) Stock Price, News & Analysis - kalkine.ca
Avalyn Pharma Q2 Results: EPS misses estimate by 22.64% - scanx.trade
Avalyn Pharma (NASDAQ:AVLN) Trading Up 8.2% Following Better-Than-Expected Earnings - MarketBeat
Form 8K Avalyn Pharma Inc. For: 12 August By Investing.com - Investing.com Nigeria
Avalyn Pharma Inc. Q2 2026: Net loss $(28.9M), EPS $(0.98) — 10-Q Summary - TradingView
Avalyn Pharma's Q2 Net Loss Widens - Yahoo Finance
Avalyn: Q2 Earnings Snapshot - AOL.com
Avalyn: Q2 Earnings Snapshot - 10TV
AVLN: Completed Phase 2b trial enrollment and secured $413.5M cash runway into 2029 - TradingView
Form 8K Avalyn Pharma Inc. For: 12 August By Investing.com - Investing.com Canada
AVLN: Net loss widened on higher R&D spend; IPO proceeds extend cash runway into 2029 - TradingView
Avalyn Pharma reports Q2 2026 net loss $28.9M; cash $413.5M, runway into 2029 - TradingView
Form 8K Avalyn Pharma Inc. For: 12 August By Investing.com - Investing.com UK
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights - marketscreener.com
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire
Avalyn Pharma Inc. (NASDAQ:AVLN) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Avalyn Pharma (AVLN): Norwest Venture Partners discloses 5.1% ownership stake - Stock Titan
Biotech Stocks At 52-Week HighsHALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE - RTTNews
Avalyn Pharma (NASDAQ:AVLN) Reaches New 52-Week HighTime to Buy? - MarketBeat
Avalyn Pharma Inc Stock (AVLN) Financials Data
There is no financial data for Avalyn Pharma Inc (AVLN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Avalyn Pharma Inc Stock (AVLN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Carroll Jill | Director |
May 01 '26 |
Buy |
18.00 |
277,778 |
5,000,004 |
2,186,562 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 01 '26 |
Buy |
18.00 |
555,555 |
9,999,990 |
2,186,562 |
2.63%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):